FDA Reels From ‘Indiscriminate’ Job Cuts Under Trump as Biopharma Appeals for Clarity
Stuart Pape and Chad Landmon examine the impact of the recent FDA layoffs, exploring the potential ripple effects within its workforce and what the agency might look like moving forward.
